ENvue Medical Inc

ENvue Medical Inc(FEED)股票分析

$1.030

-0.713 (-69.25%)收盤時

Loading chart…
最高
3.420
開盤
3.340
成交量加權均價
1.76
成交量
1.22M
市值
—
最低
0.840
成交金額
2.16M
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.

AI 分析 of ENvue Medical Inc (FEED)

賣出

ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.

估值指標

ENvue Medical Inc(FEED)目前預期本益比為 0.00,5 年平均預期本益比為 -0.00。

預期本益比

嚴重高估
5 年均值 P/E
-0.00
目前P/E
0.00
高估
-0.00
低估
-0.00

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.88
目前P/S
0.00
高估
1.04
低估
0.72

事件時間軸

2026-10-29 (ET)

08:00:00

ENvue Medical Begins UroShield Production in the U.S.

2026-10-26 (ET)

08:00:00

ENvue Medical CEO Emphasizes Profitability Goals and Market Expansion

2026-09-15 (ET)

13:00:00

ENvue Medical's Nasdaq Listing Request Denied

2026-09-09 (ET)

09:30:00

ENvue Medical Resumes Commercial Shipments of PainShield

2026-08-10 (ET)

16:30:00

ENvue Medical Files $50M Mixed Securities Shelf

資訊

FEED 常見問題 —— 由 Alphio AI 解答

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. It operates in the Healthcare sector.

ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易